Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2016
Published Jul 20, 2016
143 pages — Published Jul 20, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2016, provides in depth analysis on Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas

  
Source:
Document ID
GMDHC0400TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Overview101
Therapeutics Development114
  Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Products under Development by Stage of Development111
  Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Products under Development by Therapy Area121
  Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Products under Development by Indication132
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Pipeline Products Glance152
  Late Stage Products151
  Early Stage Products161
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Products under Development by Companies175
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Products under Development by Universities/Institutes222
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Therapeutics Assessment245
  Assessment by Monotherapy/Combination Products241
  Assessment by Mechanism of Action251
  Assessment by Route of Administration262
  Assessment by Molecule Type281
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Companies Involved in Therapeutics Development2922
  Aerie Pharmaceuticals, Inc.291
  Aptose Biosciences Inc.301
  Astex Pharmaceuticals, Inc.311
  AstraZeneca Plc321
  Bristol-Myers Squibb Company331
  Celon Pharma Sp. z o.o.341
  Concert Pharmaceuticals, Inc.351
  CTI BioPharma Corp.361
  Daiichi Sankyo Company, Limited371
  Eli Lilly and Company381
  Genentech, Inc.391
  Gilead Sciences, Inc.401
  Incyte Corporation411
  Merck &Co., Inc.421
  Nerviano Medical Sciences S.r.l.431
  Nippon Shinyaku Co., Ltd.441
  Novartis AG451
  SOM Innovation Biotech SL461
  Theravance Biopharma, Inc.471
  Tolero Pharmaceuticals, Inc.481
  Tragara Pharmaceuticals, Inc.491
  Vectura Group Plc501
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Drug Profiles5165
  AC-410 Drug Profile511
  AR-13154 Drug Profile521
  AT-9283 Drug Profile532
  AZD-1480 Drug Profile552
  baricitinib Drug Profile577
  BVB-808 Drug Profile641
  CHZ-868 Drug Profile651
  CPL-407105 Drug Profile661
  CPL-40722 Drug Profile671
  CTP-543 Drug Profile681
  lestaurtinib Drug Profile691
  MA-2014 Drug Profile701
  momelotinib dihydrochloride Drug Profile715
  MRLB-11055 Drug Profile761
  NMSP-113 Drug Profile771
  NMSP-953 Drug Profile781
  NS-018 Drug Profile791
  pacritinib Drug Profile8011
  ruxolitinib phosphate Drug Profile9113
  SAR-317461 Drug Profile1041
  Small Molecule to Inhibit JAK2 for Leukemia Drug Profile1051
  Small Molecules to Inhibit JAK2 for Cancer Drug Profile1061
  Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders Drug Profile1071
  Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders Drug Profile1081
  Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms Drug Profile1091
  TD-1473 Drug Profile1101
  TG-02 Drug Profile1113
  TP-0413 Drug Profile1141
  VR-588 Drug Profile1151
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Dormant Projects1166
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Discontinued Products1222
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Featured News &Press Releases12418
  Jun 23, 2016: FDA Grants Breakthrough Therapy Designation for Incyte s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD)1241
  Jun 10, 2016: New Phase 3 Data Show Jakafi (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera1241
  Jun 09, 2016: Baricitinib Significantly Reduces Joint Damage Progression In Rheumatoid Arthritis In Patients Who Do Not Respond To Conventional DMARDs1251
  Jun 09, 2016: Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)1262
  Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor1281
  Jun 07, 2016: Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting1294
  Jun 07, 2016: Results Of Clinical And Patient-Reported Outcomes Data For Baricitinib In Patients With Rheumatoid Arthritis To Be Presented At Annual European Congress Of Rheumatology1331
  Jun 06, 2016: Five-year Results from Phase 3 Study of Jakafi (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis1341
  May 19, 2016: CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting1351
  May 19, 2016: Incyte Highlights Jakafi (ruxolitinib) Abstract to be Presented at the 2016 ASCO and EHA Annual Meetings1361
  May 19, 2016: Concert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata1371
  May 04, 2016: Concert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata1381
  May 03, 2016: Parkinson's disease pathogenesis reduced in rat model by a cell-signaling inhibitor drug1382
  Apr 20, 2016: Preclinical Data Presented At AACR Indicate Pacritinib Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment1401
  Apr 13, 2016: CTI BioPharma Announces Presentation on pacritinib at the American Association of Cancer Research Annual Meeting1402
Appendix1422
  Methodology1421
  Coverage1421
  Secondary Research1421
  Primary Research1421
  Expert Panel Validation1421
  Contact Us1421
  Disclaimer1431

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tyrosine-Protein-Kinase-JAK2-Janus-Kinase-2-or-JAK2-or-EC-2-7-10-2-Pipeline-Review-H2-2016-2088-16282>
  
APA:
Global Markets Direct - Market Research. (2016). Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tyrosine-Protein-Kinase-JAK2-Janus-Kinase-2-or-JAK2-or-EC-2-7-10-2-Pipeline-Review-H2-2016-2088-16282>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.